Abstract 387
Background
To evaluate the effect of the varied histological subtypes on clinical outcome and to determine the prognostic implications of mucinous adenocarcinoma (MAC) and signet ring cell carcinoma (SRCC) compared with common adenocarcinoma (AC).
Methods
A total of 9015 patients with colorectal adenocarcinoma undergoing definitive surgery between 2007 and 2015 at FUSCC were enrolled in this study. After 1010 of these patients were excluded because of neoadjuvant therapy, 8005, including 7502 AC, 428 MAC and 75 SRCC, remained for analysis, where clinical, histopathological, and survival data were analyzed.
Results
MAC and SRCC were more common in right-sided colon cancer together with male or young patients, compared to AC, with a higher probability to develop lymph node metastasis, lymphovascular invasion and perineural invasion. As for survival outcomes, we found that the 5-year OS of SRCC was significantly lower than that of MAC and AC, while the 5-year OS of MAC is much lower than that of AC. However, in multivariable analysis, the difference in survival between SRCC, MAC and AC was no longer significant, especially when stratified by N stage.
Conclusions
MAC and SRCC are rare subtypes of colorectal cancer with a higher T stage, N stage as well as higher invasion ability. However, neither MAC or SRCC was an independent predictor of decreased survival in multivariate analysis.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Shanghai Cancer Center Fudan University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
780 - The adipocyte suppresses the inhibitory role of hsa_circ_0000190 in the metastasis of breast cancer cells
Presenter: Xiu Chen
Session: Poster display - Cocktail
Resources:
Abstract
782 - CircASS1 suppressed the invasion and metastasis ability of breast cancer cell line by targeting gene ASS1 and harboring miR-4443
Presenter: Junchen Hou
Session: Poster display - Cocktail
Resources:
Abstract
916 - Ex-vivo drug sensitivity of primary breast cancer stems cell populations to potentiate therapeutic strategy for treatment resistant breast cancer
Presenter: Sourav Nandi
Session: Poster display - Cocktail
Resources:
Abstract
928 - Molecular Tumor Board (MTB): development of clinical pathways for precision medicine. Experiences of Center for Breast cancer at National cancer center, Korea
Presenter: In Hae Park
Session: Poster display - Cocktail
Resources:
Abstract
1274 - MicroRNA based immune response signature identifies poor prognostic subgroup within ER negative breast cancers
Presenter: Savitha Rajarajan
Session: Poster display - Cocktail
Resources:
Abstract
165 - The clinical efficacy of apatinib combined with Xeloda in advanced triple negative breast cancer
Presenter: YiHui Li
Session: Poster display - Cocktail
Resources:
Abstract
561 - Quality of life and psychosocial needs of metastatic breast cancer patients
Presenter: Tahir Mehmood
Session: Poster display - Cocktail
Resources:
Abstract
697 - TC-1 mediate the TBC1D3 oncogene induced migration of MCF-7 breast cancer cells
Presenter: Yong Shen
Session: Poster display - Cocktail
Resources:
Abstract
784 - RelB facilitates cell migration and invasion in breast cancer via MMP1 upregulation
Presenter: Mei Wang
Session: Poster display - Cocktail
Resources:
Abstract
921 - Re-challenging eribulin in patients with ER+HER2- metastatic breast cancer: A single-institution experience
Presenter: Junichiro Watanabe
Session: Poster display - Cocktail
Resources:
Abstract